Fig. 3

Change of mean pulmonary arterial pressure during long-term follow-up according to treatment subgroups. Patients receiving ambrisentan throughout EDITA-ON had a reduction in mPAP, while patients with no treatment in EDITA-ON showed an increase in mPAP (ANOVA p = 0.024)